Search results
Showing 691 to 705 of 749 results for adult social
Discontinued Reference number: GID-TA11351
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women and pregnant trans men and non-binary people whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Show all sections
Sections for NG195
- Overview
- Using this guideline
- Information and support for parents and carers
- Prevention and risk reduction
- Risk factors and clinical indicators: early-onset neonatal infection
- Risk factors and clinical indicators: late-onset neonatal infection
- Investigations before starting antibiotics for early-onset or late-onset neonatal infection
- Principles around use of antibiotics for early-onset or late-onset neonatal infection
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
Discontinued Reference number: GID-TA10234
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development Reference number: GID-TA10489 Expected publication date: TBC